Keywords
How to Cite
Abstract
Clinical cases of uterine leiomyoma with secondary lung involvement are described. The results of X-ray, computerized tomography, and histological examination of lung specimens, as well as those of heterozygosity and microsatellite instability are presented. Our own experience and the few descriptions available to date in the literature confirm the pseudo tumorous nature of benign uterine leiomyoma with lung involvement which should be considered as nodular dyshormonal hyperplasia. The signs of genetic instability ՛s identification do not allow to differentiate clearly between the benign or malignant nature of the disease. The key role in the differential diagnosis of uterine leiomyoma with lung involvement and leiomyosarcoma belongs to unprejudiced clinical observation.
References
Mantel F, Glatz S, Toussaint A et al. Long-term safety and efficacy of fractionated stereotactic body radiation therapy for spinal metastases // Strahlenther Onkol. 2014;190(12):1141–8. https://doi:10.1007/s00066-014-0706-1
Erler D, Brotherston D, Sahgal A. Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases // Radiother Oncol. 2018;127(2):304–309. https://doi:10.1016/j.radonc.2018.03.030
Sze WM, Shelley M, Held I et al. Palliation of metastatic bone pain: singl fraction versus multiple-fraction radiotherapy — a systematic review of randomised trials // Clin Oncol. 2003;15(6):345–352. https://doi:10.1016/s0936-6555(03)00113-4
Wu J, Wong R, Johnston M et al. Meta-analisis of dose- fractionation radiotherapy trials for the palliation of painful bone metastases // Int J Radiat Oncol Biol Phys. 2003;55(3):594–605. https://doi:10.1016/s0360-3016(02)04147-0
Takahashi Т, Nishimura К, Yamano T, Gika M. Role of Palliative Radiotherapy for Bone Metastasis // J Palliat Care Med. 2014;4:171. https://doi:10.4172/2165-7386.1000171
Бычкова Н.М., Хмелевский Е.В. Особенности метастатического поражения костей при различных первичных опухолях и их значение для дистанционной лучевой терапии // Онкология. Журнал им. П.А. Герцена. 2016;5(6):12 [Bychkova N.M., Khmelevsky EV. Features of metastatic bone involvement in different primary tumors and their implications for external beam radiotherapy // Onkologiya Zhurnal imeni P.A. Gertsena 2016;5(6):12. (In Russ.)] https://doi.org/10.17116/onkolog20165612-20
World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO Publication № 48, Geneva. https://doi:apps.who.int/iris/handle/10665/37200
Amundson S, Do K, Vinikoor L et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen // Cancer Res. 2008;68(2):415–24. https://doi:10.1158/0008-5472.CAN-07-2120
D'Andrea FP, Safwat A, Burns JS et al. Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells // Int J Radiat Biol. 2012;88(6):457–65. https://doi:10.3109/09553002.2012.683509
Hill RP. The changing paradigm of tumor response to irradiation // Br J Radiol. 2017;90:20160474. https://doi.org/10.1259/bjr.20160474
He Q, Tong Y, Ye Z et al. A multiple genomic data fused SF2 prediction model, signature identification, and gene regulatory network inference for personalized radiotherapy // Technol Cancer Res Treat. 2020;19:1533033820909112. https://doi:10.1177/1533033820909112
Shahbazian D, Bindra R, Kluger H, Glazer P. Radiation sensitivity and sensitization in melanoma // Pigment Cell Melanoma Res. 2013;26(6):928–30. https://doi:10.1111/pemr.12147
Sambade M, Peters E, Thomas N et al. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032 // Radiother Oncol. 2011;98(3):394–9. https://doi:10.1016/j.radonc.2010.12.017
Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study // Int J Radiat Oncol Biol Phys. 1986;12(6):867–872. https://doi:10.1016/0360-3016(86)90378-0
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021